Blog

/Blog
All Articles
July 31, 2019

Complying With Colorado’s New Drug Price Transparency Law

This POV describes Colorado House Bill 19-1131 and how it could affect pharma marketers. The bill requires that any one-to-one communications between pharmaceutical representatives (or anyone communicating on their behalf) and prescribers must include written information about the wholesale cost of a drug, as well as the names of at least three generic equivalents. The law goes into effect on August 2, 2019.

July 16, 2019

California’s New Data Privacy Law: New Thinking on its Implications for Pharma

Last fall, we published a POV called “Should Pharma Care About California’s New Data Privacy Law?” Since then, we’ve been monitoring the legislative process and the discussions and reactions of opinion leaders. This updated POV provides the latest thinking on this law and its implications for pharma marketers.

July 16, 2019

Six Ways Data Science Can Create More Efficient Marketing Experiences

Data science: a term that always sounds cutting-edge. While discussions of personalized medicine and the related science of gene therapy and similar advances become more science than science fiction, pharma marketing is beginning to step into the individualized, independent experience economy, as well. What is the experience economy? It’s not

June 21, 2019

Mary Meeker’s 2019 Internet Trends Report — What Pharma Marketers Need to Know

Mary Meeker, tech maven and founder of the newly formed Bond Capital -- and former partner at venture-capital firm Kleiner Perkins Caufield & Byers -- recently presented her latest internet trends report at Recode’s Code 2019 conference, and this one was nearly as large as the 2017 presentation. This recap highlights what’s relevant for pharma marketers.

Load More Posts